Overview
AQST market data
Price History
AQST price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.78 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -137.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.93 – $7.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $532.8M · P/B 15.59 · P/S 10.60.
Company News
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M EstimateBenzinga · Aug 11, 2026, 8:01 PM
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M EstBenzinga · Aug 11, 2026, 8:01 PM
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful StudyBenzinga · Aug 10, 2026, 6:06 PM
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On MondayBenzinga · Aug 10, 2026, 2:11 PM
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual filmBenzinga · Aug 10, 2026, 1:21 PM
Aquestive Says Anaphylm Human Factors Study Cut Median Pouch-Opening Time To 3 Seconds From 17, With NDA Resubmission On Track For Q3 2026Benzinga · Aug 10, 2026, 11:13 AM
8-K filing — Aquestive Therapeutics, Inc. (AQST)SEC EDGAR · Aug 10, 2026, 11:05 AM
Aquestive Therapeutics Files Prospectus For Offering 230,271 Common Shares On Behalf Of Selling ShareholdersBenzinga · Jun 26, 2026, 8:30 PM